NCT01113281已完成1 期
Phase Ib Open Label, Randomized, Controlled, Dose-Escalation Study to Evaluate Safety and Immunogenicity of VPM1002 in Comparison With BCG in Healthy Volunteers in South Africa
适应症
干预措施
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 24
- 试验地点
- 2
- 主要终点
- Safety: physical examination, vital signs, electrocardiogram, liver sonography, laboratory safety parameters, tolerability, recording of concomitant medication and adverse events
研究概览
简要总结
Goal of VPM is the development of a recombinant urease C-deficient listeriolysin expressing BCG vaccine strain (VPM1002) as a safe, well tolerated and efficacious vaccine against tuberculosis (TB) for residents in endemic areas and persons at risk in non-endemic areas. The new vaccine should be at least as potent as the current strain and should be safer than BCG (Kaufmann, 2007a; Grode et al., 2005). The vaccine is formulated as live lyophilised bacteria to be re-suspended before intradermal injection. The preceding clinical trial in 80 volunteers in Germany indicated immunogenicity and safety being sufficient for proceeding with the clinical development. Hence, the current study is commenced in South Africa, a country highly endemic for tuberculosis.
24 volunteers were randomly allocated to 4 groups each with 6 adult healthy volunteers.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Prevention
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 45 Years（Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Adult volunteers 18 to 45 years of age
- •Volunteers must use acceptable contraception and avoid pregnancy for the duration of the study (6 months)
- •Healthy (medical history, physical examination, vital signs, ECG and laboratory tests at screening)
- •No signs of active or latent tuberculosis infection
- •BMI of 19 - 33 kg/m2
- •Subjects must be able and willing to comply with the study protocol, available and willing to complete all study measurements and have signed an Informed Consent form approved by the Ethics Committee.
- •Reachable by phone during the whole study period (approximately 6 months).
- •Negative test for HIV1 and HIV2, hepatitis B surface antigen and antibody to hepatitis C virus.
- •No anamnestic evidence for a primary or secondary immunodeficiency.
- •No skin eczema lesion at the intended injection site.
- •No anamnestic predisposition for scarring badly or for keloid formation.
- •No other vaccination during eight weeks before the current study.
- •No participation in another clinical trial within 3 months before study vaccination and the 6 months of the current study.
- •No prior participation in a TB vaccine trial.
- •Able and willing to abstain from strenuous physical exercise 24 hours before screening examination, and 24 hours before vaccination
排除标准
- •History of prior TB disease
- •History of anaphylaxis or severe allergic reactions
- •Known allergies to any component of the investigational or reference product or known history of severe skin reaction against the Tuberculin test
- •Presence of any person in the household of the volunteer with active tuberculosis disease
- •Tuberculin-PPD-in-vivo-test equal or more than 10 mm before baseline
- •systemic disorders which could interfere with the interpretation of the study results or compromise the health of the volunteers
- •BCG-vaccination during 10 years before study vaccination
- •Acute fever or fever in the last 7 days before dosing
- •Any malignant condition
- •Concomitant treatment with medication that may affect immune function during 3 months before study vaccination and the 6 months of current study. No oral antibiotics during the 14 days before study vaccination and no injectable antibiotics during the 28 days prior to vaccination.
- •Treatment with blood products in the past 6 months up to end of study.
- •Any clinically significant laboratory abnormalities on screened blood samples.
- •A history of drug or alcohol abuse
- •Positive test for drugs of abuse on urine testing at screening
- •Blood donation for non study-related purposes within 3 months before and during the entire duration of the study
- •Clinically relevant result from sonographic liver imaging
- •Professional or regular contact with live animals for food production
研究组 & 干预措施
VPM1002 in three dosages
Experimental
干预措施: VPM1002 live vaccine (Biological)
BCG
Active Comparator
干预措施: commercially available live vaccine BCG (Biological)
结局指标
主要结局
Safety: physical examination, vital signs, electrocardiogram, liver sonography, laboratory safety parameters, tolerability, recording of concomitant medication and adverse events
时间窗: baseline, days 2, 7, 14, 28, 56, and month 6
次要结局
- Immunogenicity: Interferon-gamma-ELISA (IFN-g-ELISA) in supernatants of peripheral blood mononuclear cells (PBMC) restimulated with tuberculin (PPD from Staten Serum Institute, Denmark)(baseline, days 14, 28, 56 and month 6)
- Immunogenicity: ELISPOT for the number of IFN-g-secreting PBMC after restimulation with PPD(baseline, days 14, 28, 56 and month 6)
- Immunogenicity: Whole Blood Assays (WBA): IFN-g-ELISA of supernatants of whole blood restimulated with PPD(baseline, days 14, 28, 56 and month 6)
- Immunogenicity: Intracellular Cytokine Staining (ICS) for IFN-g, TNF-a and IL-2 in CD4+ and CD8+ lymphocytes upon stimulation with PPD(baseline, days 14, 28, 56 and month 6)
- Immunogenicity: ICS with other triple combinations of markers in CD4+ and CD8+ lymphocytes upon stimulation with PPD(baseline, days 14, 28, 56 and month 6)
- Immunogenicity: Antigen-85B (Ag85B) and BCG as recall antigens for ELISA, ELISPOT, WBA and ICS(baseline, days 14, 28, 56 and month 6)
- Immunogenicity: serum antibodies against PPD or Ag85B(baseline, days 14, 28, 56 and month 6)
研究者
研究点 (2)
Loading locations...
相似试验
已完成
1 期
Dose-Escalation Study on Safety and Immunogenicity of VPM1002 in Comparison With BCG in Healthy Male VolunteersHealthyTuberculosisNCT00749034Vakzine Projekt Management GmbH80
已完成
2 期
Study to Evaluate Safety and Immunogenicity of VPM1002 in Comparison With BCG in Newborn Infants in South AfricaTuberculosisNCT01479972Vakzine Projekt Management GmbH48
已完成
2 期
Study to Evaluate the Safety and Immunogenicity of VPM1002 in Comparison With BCG in HIV-exposed/-Unexposed Newborn Infants in South AfricaTuberculosisNCT02391415Serum Institute of India Pvt. Ltd.416
撤回
不适用
An Exploratory Clinical Trial to Generate Whole Blood Samples for Analysing Genetic PolymorphismsDiabetes Type 1Diabetes Type 2PrediabetesNCT02057497Profil Institut für Stoffwechselforschung GmbH
进行中（未招募）
1 期
A Study of GZR18 Tablet in Chinese Healthy SubjectsDiabetes Mellitus, Type 2NCT06554054Gan and Lee Pharmaceuticals, USA92